5 Key Takeaways

• 1

  Intellia Therapeutics reported positive Phase 3 results for its CRISPR therapy lonvoguran ziclumeran, reducing hereditary angioedema attacks by 87%.

• 2

  62% of patients treated with lonvo-z experienced complete freedom from attacks and ongoing medication during the six-month evaluation.

• 3

  Flagship Pioneering launched Serif Biomedicines to develop programmable DNA medicines, combining features of mRNA and gene therapy.

• 4

  Cabaletta Bio partnered with Cellares to scale CAR-T manufacturing, aiming to produce thousands of patient-specific batches annually.

• 5

  Research indicates that senescent immune cells may limit the effectiveness of CAR-T therapy, suggesting pre-treatment profiling could improve outcomes.